Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
Ligand To Report Third Quarter 2023 Financial Results On November 8
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
Ligand Appoints Martine Zimmermann to its Board of Directors
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Ligand Reports Second Quarter 2023 Financial Results
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Ligand To Report Second Quarter 2023 Financial Results On August 8
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
